NewAmsterdam Pharma N.V. (NAMS)
NewAmsterdam Pharma N.V. (NAMS) Stock Price, Analysis & Data
| Bid | 19.66 |
| Market Cap | 3.25B |
| Revenue (ttm) | 7.12M |
| Net Income (ttm) | -259.5M |
| Beta | 0.11 |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | n/a |
| Forward PE | -17.89 |
| P/B (ttm) | 5.19 |
| P/S (ttm) | 467.17 |
| Earnings Date | Nov 4, 2026 |
| Ask | 33.17 |
| Volume | 1,617,537 |
| Avg. Volume (20D) | 1,184,519 |
| Open | 27.60 |
| Previous Close | 27.62 |
| Day's Range | 27.45 - 28.16 |
| 52-Week Range | 23.05 - 42.20 |
| Analyst | Strong Buy |
| Price Target | 51.9 (86.49%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NAMS
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is ...
Financial Performance
In 2025, NewAmsterdam Pharma's revenue was 22.5M, a decrease of -50.61% compared to the previous year's 45.56M. Earnings were -203.82M, a decrease of -15.64%.
Financial StatementsAnalyst Forecast
According to 15 analyst ratings, the average rating for NAMS stock is "Strong Buy". The 12-month stock price forecast is 51.9, which is upside of 86.49% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
